Marcus Quinkler

Marcus Quinkler

Auto-generated profile, based on publicly available information

Marcus Quinkler

Endocrinology in Charlottenburg, Berlin, Germany (M.Q.).

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
JLJacques W M Lenders
Jacques W M Lenders
PMPaolo Mulatero
Paolo Mulatero
Jacopo BurrelloJacopo Burrello
Jacopo Burrello
MRMarietta Rottenkolber
Marietta Rottenkolber
CAChristian Adolf
Christian Adolf
HWHolger S Willenberg
Holger S Willenberg

7 June 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MFMartin Fassnacht
Martin Fassnacht
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
BABruno Allolio
Bruno Allolio
EBEric Baudin
Eric Baudin
HHHarm Haak
Harm Haak
BSBritt Skogseid
Britt Skogseid
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. For first-line therapy, patients in the EDP–mitotane group had a significantly higher response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P=0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP–mitotane group and 2.2 months in the streptozocin–mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments. Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, NCT00094497.)

20 April 2014 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GAGuillaume Assié
Guillaume Assié
ELEric Letouzé
Eric Letouzé
MFMartin Fassnacht
Martin Fassnacht
AJAnne Jouinot
Anne Jouinot
WLWindy Luscap
Windy Luscap
JBJérôme Bertherat
Jérôme Bertherat

7 January 2009 in Cancer
Verified
Journal Article
Open access
PDF file
MFMartin Fassnacht
Martin Fassnacht
SJSarah Johanssen
Sarah Johanssen
MQMarcus Quinkler
Marcus Quinkler
PBPeter Bucsky
Peter Bucsky
HWHolger S. Willenberg
Holger S. Willenberg
FTfor the German Adrenocortical Carcinoma Registry Group and the European Network for the Study of Adrenal Tumors
for the German Adrenocortical Carcinoma Registry Group and the European Network for the Study of Adrenal Tumors
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy, and it was only in 2004 that the International Union Against Cancer (UICC) defined TNM criteria and published the first staging classification. However, to date, the prognostic value of the proposed classification has not been evaluated.METHODS: The German ACC Registry comprising 492 patients was searched for patients who were diagnosed between 1986 and 2007 with detailed information on primary diagnosis and a minimum follow‐up of 6 months. Patients were assigned to UICC tumor stage, and disease‐specific survival (DSS) was assessed. In addition, the contribution of potential risk factors for DSS was evaluated.RESULTS: In total, 416 patients with a mean follow‐up of 36 months met the inclusion criteria (stage I, n = 23 patients; stage II, n = 176 patients; stage III, n = 67 patients; stage IV, n = 150 patients). Kaplan‐Meier analysis revealed a stage‐dependent DSS. However, DSS in patients with stage II ACC did not differ significantly from DSS in patients with stage III ACC (hazard ratio, 1.38; 95% confidence interval, 0.89‐2.16). Furthermore, patients who had stage IV ACC without distant metastases had an improved DSS compared with patients who had metastatic disease (P = .004). An analysis of different potential risk factors for defining stage III ACC revealed important roles in DSS for tumor infiltration in surrounding tissue, venous tumor thrombus (VTT), and positive lymph nodes; whereas tumor invasion in adjacent organs carried a prognosis similar to that of infiltration in surrounding tissue only.CONCLUSIONS: The 2004 UICC staging classification for ACC has significant limitations. On the basis of the current analysis, a revised classification with superior prognostic accuracy is proposed (the European Network for the Study of Adrenal Tumors classification). In this system, stage III ACC is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or VTT; and stage IV ACC is restricted to patients with distant metastasis. Cancer 2009. © 2009 American Cancer Society.

1 May 2016 in Cancer Cell
Verified
Journal Article
Closed access
SZSiyuan Zheng
Siyuan Zheng
ACAndrew D. Cherniack
Andrew D. Cherniack
NDNinad Dewal
Ninad Dewal
RMRichard A. Moffitt
Richard A. Moffitt
LDLudmila Danilova
Ludmila Danilova
TDTimothy Defreitas
Timothy Defreitas

17 February 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FBFelix Beuschlein
Felix Beuschlein
Sheerazed BoulkrounSheerazed Boulkroun
Sheerazed Boulkroun
AOAndrea Osswald
Andrea Osswald
TWThomas Wieland
Thomas Wieland
HNHang N Nielsen
Hang N Nielsen
MRMartin Reincke
Martin Reincke